PMS55 IMPACT of Tanezumab on Health Status, Daily Activity and Work Productivity in Adults with Moderate-to-Severe Osteoarthritis

Abstract

Tanezumab is being investigated for the treatment of moderate-to-severe symptomatic osteoarthritis (OA). This pooled analysis of two phase 3 studies evaluated the impact of tanezumab at week 16 on health status, assessed by the EuroQol 5 Dimension 5 level (EQ-5D-5L), and daily activity and work productivity, assessed by the Work Productivity and Activity Impairment (WPAI) questionnaire. Subcutaneous tanezumab (2.5 mg and 5 mg) was tested in double-blind, placebo-controlled, 16-week (NCT02697773) and 24-week (NCT02709486) studies in patients with moderate-to-severe OA of the hip or knee. At baseline and week 16, in both studies, patients completed EQ-5D-5L and the WPAI activity impairment item. Those currently employed also completed WPAI work time missed, impairment while working and overall work impairment items. The pooled population included 1,545 patients, of whom 576 were employed at baseline. Improvements in EQ-5D-5L utility score at week 16 were significantly greater for the tanezumab 2.5 mg group (difference in least squares means [95% confidence interval], 0.03 [0.01, 0.05], P=0.0083) compared with placebo. Improvements in percent activity impairment (–5.92 [–8.87, –2.98], P<0.0001), percent impairment while working (–7.34 [–13.01, –1.68], P=0.0112) and percent overall work impairment (–7.44 [–13.22, –1.67], P=0.0116) at week 16 were significantly greater for the tanezumab 2.5 mg group compared with placebo. for the tanezumab 5 mg group were generally comparable to the tanezumab 2.5 mg group, although compared with placebo, improvement in percent work time missed was significantly greater for the tanezumab 5 mg group (–3.40 [–6.47, –0.34], P=0.0294), but not the tanezumab 2.5 mg group (–0.66 [–3.63, 2.32], P=0.6637). This pooled analysis showed that health status, daily activity and work productivity were significantly improved at week 16 following subcutaneous tanezumab administration in patients with moderate-to-severe OA. Funded by Pfizer and Lilly.